Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by Eastern Hepatobiliary Surgery Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Eastern Hepatobiliary Surgery Hospital
ClinicalTrials.gov Identifier:
NCT00822562
First received: January 6, 2009
Last updated: January 15, 2009
Last verified: January 2009
  Purpose

In this study, we intend to divide the subjects who have been confirmed recurrent HCC into two groups: Group A: treatment with pure surgery or Group B: treatment with pure radio frequency. We will compare the non-tumor survival time, long-term survival rate between the two groups, summarize the merits and demerits of both groups, and try to establish a standardized therapy and treatment for the this kind of patients through prospective studies on the molecular biological difference of pathological samples between the first and second surgeries.


Condition Intervention
Hepatocellular Carcinoma
Other: PRFA or PMCT
Procedure: surgery

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer

Resource links provided by NLM:


Further study details as provided by Eastern Hepatobiliary Surgery Hospital:

Primary Outcome Measures:
  • Overall survival rate [ Time Frame: two years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • non-tumor life span, intra-liver recurrence rate, metastasis rate [ Time Frame: two years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: January 2009
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Procedure/Surgery
surgery
Procedure: surgery
only surgery
Other Name: surgery
No Intervention: Procedure
PRFA or PMCT
Other: PRFA or PMCT
PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
Other Name: PRFA or PMCT

Detailed Description:

The recurrence and metastasis of primary liver cancer (PLC) have always been a tough problem for surgeons. Gu Hong-guang reported the five years recurrence rate in PLC subjects reached 75~100%, among which 60% were discovered within three years after surgeries, with the peak appearing at 18~24 months. According to a report delivered by Zhong-Shan Hospital, the recurrence rate of small HCC was 40%, and that of large HCC was 1.9 times of small HCC. Chen Han agreed that the recurrence rate in 1~2 years reached 71.6%, while in 2~11 years was 28.4%. With the rapid development of iconography and surgical techniques, it is possible for surgeon to resect the recurrent HCC now. In 1986, Nagasue et al. reported the excision of recurrent HCC and proved that comparing with non-surgical treatment, subjects with recurrent HCC excision got a higher survival rate. However, the excision rate of recurrent HCC has always been an arguable point. Nakajima et al. suggested the excision rate in 133 subjects was 24%, while Matsuda et al. agreed that in 91 subjects reached 44%, and Zhoo reported that in 384 subjects was 35%; Kakazu et al. insisted that in 286 subjects was 17%; Nagasue et al. said that in 290 subjects was 30%; Shoto et al. reported that in 341 subjects was 19% and Poon et al. advocated that in 244 subjects was 10%. He Sheng summarized the 1295 subjects in recent five years, and only 106 of them had the opportunities to have excision again (8.18%). Sugimachi, Minagawa et al. reported separately the 5 year survival rate in recurrent HCC subjects were 47.5% and 56.0%, which showed no significant difference with the first surgeries, but better therapeutic effects, meanwhile, third and forth surgeries could also get similar survival rate, which indicated that surgical excision is a vital treatment in recurrent HCCs. Chen Han in our hospital reported the first, third, fifth, and tenth year survival rate in 162 recurrent HCC subjects who underwent first surgical treatment were separately 96.8%, 66.7%, 43.6% and 21.8%; while that in subjects who received second surgical treatment were separately 94.7%, 44.9% and 25.0% at the first, third, and fifth year (mean survival time was 45 months, and average survival time was 54 months).

In this study, we intend to divide the subjects who have been confirmed recurrent HCC into two groups: Group A: treatment with pure surgery or Group B: treatment with pure radio frequency. We will compare the non-tumor survival time, long-term survival rate between the two groups, summarize the merits and demerits of both groups, and try to establish a standardized therapy and treatment for the this kind of patients through prospective studies on the molecular biological difference of pathological samples between the first and second surgeries.

  Eligibility

Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 20~60 years old;
  2. diagnosed HCC pathologically, and confirmed recurrent HCC through ultrasonic B, CT, MRI or DSA test;
  3. has a good condition in vital organs such as heart, lung, and kidney;
  4. has a good liver function: Child A level, or nearly A level after hepatoprotection treatment;
  5. solitary small cancer focus (diameter <5cm), or the number of recurrent HCC focus is no more than three and all of them grow in the same lobe of liver;
  6. without jaundice (not including jaundice in the bile ducts), without ascites or extensive metastasis outside the liver;
  7. without invasion to portal vein.

Exclusion Criteria:

  1. subjects refuse to participate in this study;
  2. subjects cannot be followed up regularly;
  3. subjects with severe heart, lung, kidney diseases;
  4. subjects with liver CP level B or C, and serum creatinine ≥2×ULN;
  5. subjects with severe bone marrow depression, such as neutrophil counting is lower than 1.5 × 109.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00822562

Contacts
Contact: Jia-he Yang, MD 0086-021-81870786 ehbhjhyang@163.com
Contact: Guo-jun Qian, MD 0086-021-81870847

Locations
China, Shanghai
Eastern Hepatobiliary Surgery Hospital Recruiting
Shanghai, Shanghai, China, 200438
Contact: Jia-he Yang, MD    0086-021-81870786    ehbhjhyang@163.com   
Sponsors and Collaborators
Eastern Hepatobiliary Surgery Hospital
Investigators
Study Chair: Feng Shen, MD Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University
  More Information

No publications provided

Responsible Party: shenfeng, Shanghai Eastern Hepatobiliary Surgery Hospital
ClinicalTrials.gov Identifier: NCT00822562     History of Changes
Other Study ID Numbers: EHBH-RCT-2008-016, ZD2008-016-P1
Study First Received: January 6, 2009
Last Updated: January 15, 2009
Health Authority: China: Ministry of Health

Keywords provided by Eastern Hepatobiliary Surgery Hospital:
hepatocellular carcinoma
surgery

Additional relevant MeSH terms:
Carcinoma
Liver Neoplasms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Adenocarcinoma

ClinicalTrials.gov processed this record on April 20, 2014